welcome to cyprotex adme
welcome to cyprotex adme
cloe predict
cloe select
cloe screen

Microsomal binding assay

Use our microsomal binding assay to improve your prediction of in vivo pharmacokinetics and drug-drug interactions by correcting for the extent of binding to microsomes.

The microsomal binding assay is one of our Cloe Screen portfolio of in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.

 

Determining the extent of microsomal binding

  • Drug that is sequestered in microsomes in vitro is presumed to be unavailable for direct interaction with metabolising enzymes, just as drug that is bound to plasma proteins and tissue macromolecules in vivo is presumed to be unable to be directly acted on by drug metabolising enzymes.
  • Microsomal binding is an important factor in the prediction of in vivo pharmacokinetics from in vitro drug metabolism data.
  • It has been recognised that correcting for nonspecific binding in the in vitro microsomal stability assays can improve the accuracy of in vivo metabolic clearance prediction(2,3,4).
  • Knowledge of fuinc has also been shown to be important for the prediction of in vivo drug-drug interactions.
  • Cloe Screen Microsomal Binding assay uses equilibrium dialysis to determine the extent at which a compound binds to microsomes (fraction unbound value).
 
‘It has been recognized that nonspecific microsomal binding in the in vitro metabolic assays can significantly affect the observed kinetics of metabolism and hamper the accurate prediction of clearance, and there are now several examples where knowledge of the extent of microsomal binding can lead to a better understanding of the relationship between in vitro metabolism and in vivo pharmacokinetics’
1Austin RP, Barton P, Cockroft SL, Wenlock MC and Riley RJ. (2002) Drug Metab  Dispos 30 (12); 1497-1503.
Protocol +
Data +
Q&A +
References

1 Austin RP et al. (2002) Drug Metab Dispos 30 (12); 1497-1503.
2 Carlile DJ et al. (1999) Br J Clin Pharmacol 47 (6); 625-635.
3 Obach RS. (1997) Drug Metab Dispos 25 (12); 1359-1369.
4 Obach RS. (1999) Drug Metab Dispos 27 (11); 1350-1359.

5 Tran TH et al. (2002) Drug Metab Dispos 30 (12); 1441-1445
6 Margolis JM and Obach RS (2003) Drug Metab Dispos 31 (5); 606-611
7 Venkatakrishnan K et al. (2000) J Pharmacol Exp Ther 293 (2); 343-350
8 Naritomi Y et al. (2001) Drug Metab Dispos 29 (10); 1316-1324

 
microsomal binding

Download a copy of the product sheet

Cloe® is a registered trade mark owned by Cyprotex PLC

careerscontactlegalprivacy
This website was last updated
on 8th September 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.